Editorial: Deciphering the microbiome's role in the progression of interstitial lung diseases
-
By
-
Roberto G. Carbone
-
Anne Marie Russell
-
June 1, 2026
-
Clinical Scorecard: Understanding the Impact of the Microbiome on the Development of Interstitial Lung Diseases
At a Glance
| Category | Detail |
|---|
| Condition | Interstitial Lung Diseases (ILD) |
| Key Mechanisms | Gut-lung microbiome imbalance (dysbiosis) leading to inflammation and immune dysregulation. |
| Target Population | Patients with interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF), sarcoidosis, and connective tissue associated ILD (CTD-ILD). |
| Care Setting | Clinical research and treatment settings. |
Key Highlights
- Dysbiosis is linked to inflammation and fibrosis in ILD.
- Altered lung microbiome correlates with disease progression and mortality in IPF.
- Fungal dysbiosis may serve as a biomarker for sarcoidosis.
- Gut-lung dysbiosis is associated with several CTD-ILDs.
- Traditional Chinese medicine shows potential in regulating lung microbiome.
Guideline-Based Recommendations
Diagnosis
- Utilize metagenomics for improved diagnostic accuracy in ILD.
Management
- Consider antifungal treatment in sarcoidosis cases.
- Explore probiotic and high fiber diets for CTD-ILD management.
Monitoring & Follow-up
- Monitor lung microbiome changes in relation to disease progression.
Risks
- Increased morbidity and mortality associated with dysbiosis in ILD.
Patient & Prescribing Data
Patients with interstitial lung diseases, particularly those with dysbiosis.
Microbiome profiling may guide personalized therapy and improve outcomes.
Clinical Best Practices
- Integrate microbiome analysis into clinical management of ILD.
- Focus on gut-lung axis modulation in treatment strategies.
Related Resources & Content
